Thermo-Fisher BRAHMS test falls short of NICE "impact evidence" needs
This article was originally published in Clinica
A highly promising innovative technology, Thermo-Fisher’s BRAHMS copeptin assay test for ruling out a suspected heart attack, has fallen short of full support for its use in the UK’s NHS, as a result of inadequate “clinical practice impact” evidence.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.